City Therapeutics raises $99.5M Series B (United States, Jun 2026)
$99.5M
$99.5M Series BGenerated social card
Headline
City Therapeutics Secures $99.5M Series B for RNAi - Ventureburn
About
City Therapeutics is a biotechnology company focused on developing RNA interference (RNAi) therapies. Their innovative platform utilizes engineered RNAi trigger molecules to deliver treatments beyond the liver, targeting diseases such as thromboembolic disorders and Stargardt disease. The recent $99.5 million funding will support the advancement of their clinical pipeline.
Article summary
City Therapeutics Secures $99.5M Series B for RNAi Ventureburn
Founder
John Maraganore
CEO & Co-founder
Investors · 8
6 hiddenRelated rounds
| Jun 29, 2026 | Omen AI | $31.0M | — | United States |
| Jun 29, 2026 | Techdollar | $3.0M | Pre-seed | United States |
| Jun 29, 2026 | Su | $3.0M | — | United States |
| Jun 29, 2026 | Warp | $60.0M | Series B | United States |